James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose th ...

Accessibility StatementSkip Navigation CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 27th FloorNew York, NY 10004[email protected] Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75, nearly 90%, from $61.99 to $6.24 per share [6].

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

MLTX INVESTORS: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses to Contact the Firm Before the Imminent December 15 Securities Class Action DeadlineNovember 20, 2025 3:46 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential viol ...

ROSEN, LEADING INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 20, 2025 2:11 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Pe ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 10, 2024, to September 29, 2025, the defendants made materially false and/or misleading statements and failed to disclose critical information regarding their drug candidate SLK and its comparison to BIMZELX [1]. - Specific allegations include: 1. Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [1]. 2. SLK's unique Nanobody structure does not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [1]. 3. The supposed increased tissue penetration of SLK does not translate to clinical efficacy [1]. 4. The defendants lacked a reasonable basis for their positive statements about SLK's superiority to monoclonal antibodies [1]. Next Steps for Shareholders - Shareholders who purchased MLTX shares during the class period are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].

MLTX LAWSUIT: MoonLake Immunotherapeutics Investors are Notified to Contact BFA Law about the Filed Securities Fraud Class Action and Important December 15 DeadlineNovember 19, 2025 3:36 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 19, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violat ...

Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class ActionNovember 19, 2025 9:12 AM EST | Source: Levi & Korsinsky, LLPNew York, New York--(Newsfile Corp. - November 19, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submissio ...